Influence of calcium ions on the structure and stability of recombinant human deoxyribonuclease I in the aqueous and lyophilized states

Journal of Pharmaceutical Sciences

Volumn 88, Issue 4, 1999, Pages 477-482

  Chen, Bei ^a   Costantino, Henry R ^b   Liu, Jun ^a   Hsu, Chung C ^a   Shire, Steven J ^a  

^a GENENTECH INC   (United States)

^b ALKERMES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DORNASE ALFA;

AQUEOUS SOLUTION; ARTICLE; CIRCULAR DICHROISM; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME STABILITY; HUMAN; INFRARED SPECTROSCOPY; LYOPHILISATE;

EID: 0032958279     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1021/js980273g     Document Type: Article

References (27)

1. Moore, S. Pancreatic DNase. In The Enzymes Vol. XIV; Academic Press: San Diego, CA, 1981; pp 281-295.
2. Poulos, T. L.; Price, P. A. Some effects of calcium ions on the structure of bovine pancreatic deoxyribonuclease A. J. Biol. Chem. 1972, 247, 2900-2904.
3. Price, P. A.; Liu, T.-Y.; Stein, W. H.; Moore, S. Properties of chromatographically purified bovine pancreatic deoxyribonuclease. J. Biol. Chem. 1969, 244, 917-923.
4. Price, P. A.; Stein, W. H.; Moore, S. Effect of divalent cations on the reduction and re-formation of the disulfide bonds of deoxyribonuclease. J. Biol. Chem. 1969, 244, 929-932.
5. 2+ on pH-induced hydrodynamic changes of bovine pancreatic deoxyribonuclease A. J. Biol. Chem. 1978, 253, 3191-3195.
6. 2+ in the activity of bovine pancreatic deoxyribonuclease. J. Biol. Chem. 1975, 250, 1981-1986.
7. 2+ binding to bovine pancreatic deoxyribonuclease A. J. Biol. Chem. 1972, 247, 2895-2899.
8. Shire, S. J. Stability characterization and formulation development of recombinant human deoxyribonuclease I [Pulmozyme®, (Dornase alpha)]. In Formulation, Characterization and Stability of Protein Drugs; Pearlman, R., Wang, Y. J., Eds.; Plenum Press: New York, 1996; pp 393-426.
9. Suck, D.; Oefner, C.; Kabsch, W. Three-dimensional structure of bovine pancreatic DNase I at 2.5 Å resolution. EMBO J. 1984, 3, 2423-2430.
10. Oefner, C.; Suck, D. Crystallographic refinement and structure of DNase I at 2 Å resolution. J. Mol. Biol. 1986, 192, 605-632.
11. Suck, D.; Oefner, C. Structure of DNase I at 2.0 Å resolutions suggests a mechanism for binding to and cutting DNA. Nature 1986, 321, 620-625.
12. Wolf, E.; Frenz, J.; Suck, D. Structure of human pancreatic DNase at 1.8 Å resolution. Protein Sci. 1995, 4, 115.
13. Nail, S. J. Formulation of Proteins and Peptides. In Controlled Drug Delivery. Challenges and Strategies; Park, K., Ed.; American Chemical Society: Washington, D. C., 1997; pp 185-203.
14. Cacia, J.; Quan, C. P.; Vasaar, M.; Sliwkowski, M. B.; Frenz, J. Protein sorting by high-performance liquid chromatography. I. Biomimetic interaction chromatography of recombinant human deoxyribonuclease I on polyionic stationary phases. J. Chromatogr. 1993, 634, 229-239.
15. Sinicropi, D.; Baker, D. L.; Prine, W. S.; Shiffer, K.; Shak, S. Colorimetric determination of DNase I activity with a DNA-methyl green substrate. Anal. Biochem. 1994, 222, 351-358.
16. Costantino, H. R.; Chen, B.; Liu, J.; Hsu, C. C.; Shire, S. J. Fourier transform infrared (FTIR) spectroscopic investigation of the secondary structure of recombinant human DNase I in the aqueous and dried states. Pharm. Pharmacol. Commun. 1998, 4, 391-395.
17. Griebenow, K.; Klibanov, A. M. Lyophilization-induced changes in the secondary structure of proteins. Proc. Natl. Acad. Sci U.S.A. 1995, 92, 10969-10976.
18. Dong, A.; Prestrelski, S. J.; Allison, S. D.; Carpenter, J. F. Infrared spectroscopic studies of lyophilization and temperature-induced protein aggregation. J. Pharm. Sci. 1995, 84, 415-424.
19. Bloemendal, M.; Johnson, W. C. Structural information on proteins from circular dichroism spectroscopy: Possibilities and limitations. In Physical Methods to Characterize Pharmaceutical Proteins; Herron, J. N., Crommelin, D. J. A., Eds.; Plenum Press: New York, 1995; pp 65-93.
20. Chan, H.-K.; Au-Yeung, K.-L.; Gonda, I. Effects of additives on heat denaturation of rhDNase in solution. Pharm. Res. 1996, 13, 756-761.
21. Costantino, H. R.; Griebenow, K.; Mishra, P.; Klibanov, A. M. Fourier transform infrared (FTIR) spectroscopic investigation of protein stability in the lyophilized form. Biochim. Biophys. Acta 1995, 1253, 69-74.
22. Hageman, M. J. Water sorption and solid-state stability of proteins. In Stability of Protein Pharmaceuticals. Part A. Chemical and Physical Pathways of Protein Degradation; Ahern, T. J., Manning, M. C., Eds.; Plenum Press: New York, 1992; pp 273-309.
23. Costantino, H. R.; Langer, R.; Klibanov, A. M. Solid-phase aggregation of proteins under pharmaceutically relevant conditions. J. Pharm. Sci. 1994, 83, 1662-1669.
24. Cleland J. L.; Powell, M. F.; Shire, S. J. The development of stable protein formulations. A close look at protein aggregation, deamidation, and oxidation. Crit. Rev. Ther. Drug Carrier Syst. 1993, 10, 307-377.
25. Hageman, M. J.; Bauer, J. M.; Possert, P. L.; Darrington, R. T. Preformulation studies oriented towards sustained delivery of recombinant somatotropins. J. Agric. Food Chem. 1992, 40, 348-355.
26. Bell, L. N.; Hageman, M. J.; Muraoka, L. M. Thermally induced denaturation of lyophilized bovine somatrotropin and lysozyme as impacted by moisture and excipients. J. Pharm. Sci. 1995, 84, 707-712.
27. Zhang, M. Z.; Pikal, K.; Nguyen, T.; Arakawa, T.; Prestrelski, S. J. The effect of the reconstitution medium on aggregation of lyophilized recombinant interleukin-2 and ribonuclease A. Pharm. Res. 1996, 13, 643-646.